Showing results (311-320 of 369) with videos related to

Sort By:
Pageof 37
JCO Clinical Cancer Informatics|January 19, 2019
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate CancerFatemeh Seyednasrollah, Devin C Koestler, Tao Wang, et al.
The Lancet. Oncology|November 20, 2016
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial dataJustin Guinney, Tao Wang, Teemu D Laajala, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancerCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyDaniel P Petrylak, Yohann Loriot, David R Shaffer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2021
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate CancerJamie M Sperger, Hamid Emamekhoo, Rana R McKay, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Nature Genetics|June 4, 2013
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasionGuocan Wang, Andrea Lunardi, Jiangwen Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY StudyAndrew J Armstrong, Susan Halabi, Jun Luo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate CancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.
Cell Reports. Medicine|February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trialCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
Pageof 37